Ireland-based Nabriva had its hopes raised when the FDA accelerated the PDUFA date of the biotech’s new antibiotic by two months. Those hopes were dashed with a cold splash of regulatory action today when the drug was rejected because of problems with a contract manufacturer in Europe.
